Characteristics of the transplant procedures
| Covariates . | No. . |
|---|---|
| Conditioning regimens | |
| Cyclophosphamide (Cy) total dose | |
| Cy 20 mg/kg | 14 |
| Cy 40 to 45 mg/kg | 53 |
| High-dose Cy (≥60 mg/kg) | 2 |
| Irradiation | |
| Total body irradiation (TBI) | 39 |
| Thoracoabdominal irradiation (TAI) | 28 |
| No irradiation | 2 |
| Details | |
| Cy 20 mg/kg + TAI ± Anti-T serotherapy | 5 |
| Cy 20 mg/kg + TBI ± Anti-T serotherapy | 7 |
| Cy 40 mg/kg + TAI ± Anti-T serotherapy | 14 |
| Cy 40-45 mg/kg + TBI ± Anti-T serotherapy | 30 |
| Cy 40 mg/kg + Arac + TAI + Anti-T serotherapy | 6 |
| Others with irradiation | 5 |
| Others without irradiation | 2 |
| Graft-versus-host disease prophylaxis | |
| Without cyclosporine A (CsA) | 4 |
| Cyclosporine A alone | 9 |
| CsA + corticosteroids | 16 |
| CsA + methotrexate ± corticosteroids | 15 |
| CsA + anti-T serotherapy + methotrexate | 5 |
| CsA + anti-T serotherapy ± corticosteroids | 20 |
| Ex vivo T-cell depletion | |
| No | 43 |
| Yes | 26 |
| Covariates . | No. . |
|---|---|
| Conditioning regimens | |
| Cyclophosphamide (Cy) total dose | |
| Cy 20 mg/kg | 14 |
| Cy 40 to 45 mg/kg | 53 |
| High-dose Cy (≥60 mg/kg) | 2 |
| Irradiation | |
| Total body irradiation (TBI) | 39 |
| Thoracoabdominal irradiation (TAI) | 28 |
| No irradiation | 2 |
| Details | |
| Cy 20 mg/kg + TAI ± Anti-T serotherapy | 5 |
| Cy 20 mg/kg + TBI ± Anti-T serotherapy | 7 |
| Cy 40 mg/kg + TAI ± Anti-T serotherapy | 14 |
| Cy 40-45 mg/kg + TBI ± Anti-T serotherapy | 30 |
| Cy 40 mg/kg + Arac + TAI + Anti-T serotherapy | 6 |
| Others with irradiation | 5 |
| Others without irradiation | 2 |
| Graft-versus-host disease prophylaxis | |
| Without cyclosporine A (CsA) | 4 |
| Cyclosporine A alone | 9 |
| CsA + corticosteroids | 16 |
| CsA + methotrexate ± corticosteroids | 15 |
| CsA + anti-T serotherapy + methotrexate | 5 |
| CsA + anti-T serotherapy ± corticosteroids | 20 |
| Ex vivo T-cell depletion | |
| No | 43 |
| Yes | 26 |